Table 2.
Clinical and Biochemical Characteristics of the Study Cohort According to Clinical Outcome
| Discharged n = 66 | Deceased n = 14 | p value | |
|---|---|---|---|
| Age (years) | 78 [72, 84] | 82 [78, 90] | 0.0218 |
| Male (n, %) | 32, 48.5 | 10, 71.4 | 0.1184 |
| Type 2 diabetes (n, %) | 18, 27.2 | 4, 28.5 | 0.9213 |
| Hypertension (n, %) | 39, 59.0 | 7, 50.0 | 0.5320 |
| Heart failure (n, %) | 8, 12.1 | 1, 7.1 | 0.5923 |
| Atrial fibrillation (n, %) | 11, 16.6 | 5, 35.7 | 0.1056 |
| ASCVD (n, %) | 15, 22.7 | 4, 28.5 | 0.6407 |
| ACEi/ARB (n, %) | 33, 50.0 | 7, 50.0 | 1.000 |
| Statins (n, %) | 17, 25.6 | 4, 28.5 | 0.8279 |
| Antithrombotic therapy (n, %) | 32, 48.5 | 9, 64.3 | 0.2827 |
| eGFR <60 mL/min/1.73m2 (n, %) | 27, 41.0 | 10, 71.4 | 0.0375 |
| Random plasma glucose (mg/dl) | 124 [107, 171] | 138 [126, 180] | 0.1246 |
| Serum creatinine (mg/dl) | 1.0 [0.8, 1.2] | 1.2 [1.0, 1.5] | 0.0250 |
| eGFR (mL/min/1.73m2) | 62.3 ± 18.2 | 50.3 ± 19.3 | 0.0299 |
| Serum Na2+ (mEq/l) | 138 [135, 140] | 137 [134, 143] | 0.9554 |
| Serum K+ (mEq/l) | 4.0 ± 0.5 | 4.2 ± 0.5 | 0.4809 |
| BUN (mmol/l) | 22 [18, 27] | 31 [18, 39] | 0.0886 |
| CRP (mg/dl) | 5.5 [2.1, 12.3] | 9.2 [5.0, 17.0] | 0.0530 |
| IL-6 (pg/mL) | 19.6 [6.8, 29.6] | 18.6 [7.4, 32.5] | 0.8098 |
| Ferritin (μg/l) | 439 [210, 816] | 690 [335, 1188] | 0.2594 |
| Fibrinogen (mg/dl) | 487 ± 142 | 581 ± 126 | 0.0249 |
| D-dimer (mg/l) | 0.5 [0.3, 0.9] | 0.4 [0.3, 1.3] | 0.6239 |
| HS Troponine (ng/l) | 25.1 ± 23.1 | 31.2 ± 17.8 | 0.4027 |
| BNP (pg/mL) | 173 ± 276 | 149 ± 137 | 0.7671 |
| pH | 7.46 ± 0.05 | 7.46 ± 0.03 | 0.9832 |
| PaO2 (mmHg) | 69.7 ± 22.4 | 67.5 ± 37.7 | 0.2274 |
| PaCO2 (mmHg) | 34.6 ± 5.0 | 33.2 ± 7.4 | 0.3194 |
| HCO3- (mmol/l) | 25.4 ± 3.0 | 23.4 ± 3.4 | 0.0400 |
| PaO2/FiO2 (P/F) (mmHg) | 281 [240, 329] | 252 [201, 290] | 0.0623 |
Notes: Wilcoxon/Kruskal–Wallis Tests (Rank Sums). Statistically significant differences are in bold.